A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13)
- 作者：Enrico Orciuolo ; Gabriele Buda ; Nadia Cecconi ; Sara Galimberti ; Mario Petrini
- 关键词：Chronic myeloid leukemia ; Imatinib mesylate ; Acute myeloid leukemia ; Cytogenetics
- 刊名：Leukemia Research
- 出版年：2007
- 期刊代码：186_01452126
- 类别：med
- 出版时间：November 2007
- 卷：31
- 期：11
- 页码：1599-1600
- 文件大小：64 K
摘要
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been reported in patients with secondary chromosome abnormalities. We report a patient who developed AML during imatinib treatment of Ph-positive CML despite a cytogenetic response and absence of secondary chromosome abnormalities. Thus, development of AML as a rare event in CML patients with cytogenetic responses to imatinib therapy does not depend on the development of secondary cytogenetic abnormalities.